|

GIC-102 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • GI Cell, Inc.1

Indications

  • Relapsed/Refractory Non-Hodgkin Lymphoma1
  • Relapsed/ Refractory Multiple Myeloma1
  • Advanced Solid Tumors1
  • Cancer1

Other1 trial

GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.